Tau Antibodies Inhibit Aggregation via Phagocytosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Alzheimer's disease and other neurodegenerative disorders associated with tau protein are inadequate in effectively inhibiting tau-associated pathologies and reducing aberrant tau transmission and aggregation.

Innovation Solution

Development of antibodies specifically binding to tau protein, such as those with mature heavy and light chain variable regions having sequences at least 90% identical to certain SEQ IDs, which can be used to treat or prevent Alzheimer's disease by inhibiting tau aggregation, deposition, and inducing phagocytosis of tau.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for Alzheimer's disease, then current standard therapy is maintained, but tau aggregation and deposition are not effectively inhibited

Engineering Contradiction:

Improveeffectiveness in inhibiting tau aggregationVSAvoidtau aggregation and deposition

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and targets specific epitopes on the tau protein (residues 23-46, 25-44, 28-41, or 30-39) using monoclonal antibodies, separating the harmful aggregated tau from healthy neural structures. This selective extraction allows the antibody to bind specifically to pathogenic tau forms and facilitate their removal through phagocytosis, directly addressing the ineffective aggregation inhibition of conventional treatments.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The monoclonal antibody serves as an intermediary substance that mediates between the tau protein and the immune system. The antibody binds to tau epitopes and facilitates phagocytosis by immune cells, creating a bridge that enables the immune system to effectively remove tau aggregates, thereby solving the problem of inadequate tau clearance in conventional Alzheimer's therapy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If current treatments are administered, then standard therapy protocol is followed, but aberrant tau transmission is not reduced

Engineering Contradiction:

Improvereduction of aberrant tau transmissionVSAvoidaberrant tau transmission

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary action by administering monoclonal antibodies that bind to tau epitopes before tau aggregation and transmission can occur. The antibody is introduced into the system in advance to preemptively bind to soluble tau forms, preventing their aggregation and transmission to neighboring neurons, thereby reducing aberrant tau transmission before it causes harm.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful soluble tau protein into a beneficial target for therapy. By designing antibodies that specifically recognize tau epitopes, the previously harmful tau protein becomes the target for selective binding and clearance. This conversion allows the immune system to selectively remove pathogenic tau while preserving healthy neural function, thereby reducing aberrant transmission.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If tau aggregation is allowed to proceed, then natural progression of disease occurs, but phagocytosis of tau is not induced

Engineering Contradiction:

Improveinduction of phagocytosisVSAvoidtau aggregation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent implements feedback by using monoclonal antibodies that continuously bind to tau epitopes, providing a feedback mechanism that activates phagocytic cells. The antibody-tau complex serves as a signal that feedback-stimulates phagocytic activity, creating a self-regulating system where bound tau continuously triggers immune clearance, thereby inducing phagocytosis without allowing uncontrolled aggregation.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibodies effectively inhibit tau aggregation and deposition, reduce aberrant tau transmission, and induce phagocytosis, providing a potential therapeutic approach for Alzheimer's and other tau-associated neurodegenerative diseases.

Implementation Method 1

an antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:15 and a mature light chain variable region at least 90% identical to SEQ ID NO:22

Methodology Applied

Scientific EffectAntigen-antibody binding: